Physician profile
Jonathan B Scott
NPI 1033645460
$6,307.54
in general payments reported to CMS, 2019-2025
31 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $93.15 · 2021: $595 · 2022: $345 · 2023: $588 · 2024: $2,418 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,914 · Education: $18.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,914.30 |
| Education | $18.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,853.82 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $743.57 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $663.52 | 2021-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $652.96 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $352.17 | 2024-2025 | Omvoh |
| Genzyme Corporation | $246.22 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $177.07 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $151.20 | 2019-2024 | |
| Gilead Sciences, INC. | $130.29 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $128.56 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $121.81 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $117.80 | 2024-2025 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $107.42 | 2024-2025 | Iqirvo |
| Pfizer INC. | $104.20 | 2024-2025 | |
| Qol Medical, LLC | $103.55 | 2021-2024 | Sucraid, Sucraid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $89.12 | 2021-2024 | Dificid |
| Madrigal Pharmaceuticals | $81.74 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $62.80 | 2023-2024 | Rebyota |
| Celgene Corporation | $59.57 | 2019-2024 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.55 | 2023-2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $55.57 | 2023-2024 | Idacio |
| Sandoz INC. | $44.10 | 2024 | Hyrimoz |
| Organon LLC | $33.80 | 2024 | |
| Braintree Laboratories, INC. | $30.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.78 | 2023 | Opdivo |
| Echosens North America, INC. | $24.53 | 2024 | Fibroscan |
| Novo Nordisk INC | $23.16 | 2024 | Wegovy |
| W. L. Gore & Associates, INC. | $18.33 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.77 | 2025 | Wainua |
| Daiichi Sankyo INC. | $14.13 | 2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.